Vadim Pospelov, CEO & Co-FounderThe proprietary platform will be able to handle genetic data efficiently and facilitate the customized design of genetic tests.
“Our goal is to streamline the path to accurate diagnostics through genetic testing and pave the way for personalized medical interventions,” says Vadim Pospelov, CEO & Co-Founder at Vita Motus.
The platform will push the limits of traditional genetic analysis, especially when it comes to precise tests in the field of oncology. Its cutting-edge two-step system will enable users to access and thoroughly examine their genetic data.
In the first step, a comprehensive genetic analysis will be performed using advanced techniques like exome or genes linked to cancer development sequencing or exosome sequencing. The second step will involve a more in-depth analysis, focusing on monitoring the mutations identified in the initial step and assessing their significance in relation to the patient's current condition, the progression of the disease, and the effectiveness of applied treatments. It will provide a holistic understanding of the genetic factors associated with oncology, offering valuable insights for personalized healthcare strategies.
Navigating the Diverse Genetic Data Challenge
Vita Motus tackles the challenge of navigating vast genetic data by integrating diverse information sources into a structured report. This ensures the identification and monitoring of relevant mutations for a comprehensive understanding of each patient's genetic landscape.
The company refines algorithms for data assembly and mutation significance prediction while developing a dedicated platform cluster for the second step of genetic testing. This cluster empowers users to design tests, enhancing precision and customization capabilities.
The platform's distinct advantage lies in facilitating the creation of personalized tests, allowing users to select specific genes or genome sites for a targeted tool to monitor their precise health state.
While the development of the platform remains a primary focus, Vita Motus is also making breakthroughs in its exosome research.
Its research confirms that saliva exosomes are a viable material for genetic testing, specifically for future use in exosomal miRNA tests to identify the risk group for liver cancer development. It has conducted studies with plasma and saliva samples from individuals at risk for liver cancer. Saliva exosomes being easy to collect biomaterial prove to be suitable for long-term storage, allowing to perform monitoring of patients at risk for years.
This is crucial as managing these risks may span years, and patients may not always seek immediate medical attention when asymptomatic. The direct transport of saliva samples from patients to the lab without intermediaries facilitates seamless, long-term monitoring for at-risk individuals.
Our goal is to streamline the path to accurate diagnostics through genetic testing and pave the way for personalized medical interventions
Pushing the Capabilities of Gene Testing through Active Research
Vita Motus is also working on other active research initiatives. Its upcoming experiments involve working with exosomes and cell cultures, particularly exploring the utility of exome sequencing to refine the extensive genetic data it encounters. Exosomes, acting as cell messengers, hold promise for liquid biopsy applications in cancer development. Unlike circulating tumor cells, exosomes are more abundant and easier to isolate, making them a viable option.
Its research plan includes incubating cancer cell lines with various plant extracts, isolating exosomes, and comparing the genetic information within them to that of the original cell lines. This research serves as a foundation for potential future projects, such as delving into exosomal mRNA and DNA, aligning with its commitment to advancing innovative approaches in genetic testing.
The core objective is to navigate genetic testing with a nuanced approach, avoiding information overload while ensuring no valuable insights are overlooked. Its commitment lies in conducting comprehensive genetic tests, diligently seeking relevant markers, and employing meticulous monitoring—a distinctive, multi-step system.
This approach, not commonplace, promises a nuanced understanding of each patient's genetic landscape, recognizing the imprudence of discarding the initial step in detecting certain mutations and abnormalities with a narrow genetic test alone.
Vita Motus is a pioneer in genetic diagnostics, propelling precision testing into the next generation. The company's visionary platform revolutionizes traditional genetic testing with a multi-step approach in oncology, ensuring a holistic understanding of genetic factors. The commitment to active research, particularly in utilizing saliva exosomes and exploring exosomal mRNA and DNA, showcases dedication to advancing innovative approaches. Vita Motus stands as a beacon, promising a nuanced comprehension of each patient's genetic landscape and setting new standards in precision healthcare.
